Achieving Liquidity In a Down Public Market
As a result of the downturn in the public markets, IPOs are no longer a liquidity event for venture capital investors in biotech companies. What are the implications for VCs if this situation persists?
As a result of the downturn in the public markets, IPOs are no longer a liquidity event for venture capital investors in biotech companies. What are the implications for VCs if this situation persists?